Biopharmaceutical company Protagonist Therapeutics, Inc. (NASDAQ:PTGX ) revealed on Thursday the receipt of three new US patents for its novel peptide clinical drug candidates PTG-200 and PTG-300.

The US Patents, which has been assigned the No. 10,023,614 and 10,035,824 , provide protection applicable to PTG-200, an orally stable interleukin-23 receptor (IL-23R) antagonist and its analogs in co-development with Janssen Biotech for inflammatory bowel diseases.

Additionally, the third US Patent, which has been assigned the No. 10,030,061, provides coverage related to the hepcidin mimetic PTG-300 and analogs in the treatment or prevention of iron overload diseases and other conditions.

According to the company, its interleukin-23 receptor antagonist peptide, PTG-200, is currently in a Phase 1 clinical trial in healthy volunteers to support a Phase 2 study in Crohn's disease. It is developing an injectable hepcidin mimetic, PTG-300, for the potential treatment of anaemia and iron overload related to rare blood diseases with an initial focus on beta-thalassemia under a Phase 1 clinical trial in normal healthy volunteers.